Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy

British Journal of Clinical Pharmacology

Volumn 69, Issue 1, 2010, Pages 38-50

  Chiarelli, Laurent R ^a   Molinaro, Mariadelfina ^b   Libetta, Carmelo ^c   Tinelli, Carmine ^d   Cosmai, Laura ^c   Valentini, Giovanna ^a   Canton, Antonio Dal ^c   Regazzi, Mario ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b Pharmacokinetics Unit   (Italy)

^c Division of Nephrology   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

IMPDH; Mycophenolic acid; Pharmacodynamics; Pharmacokinetics; Rejection; Renal transplant

Indexed keywords

INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG ACTIVITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FOLLOW UP; HUMAN; KIDNEY GRAFT; LONG TERM CARE; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; LINEAR MODELS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 72949123024     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03542.x     Document Type: Article

References (41)

1. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996 28 : 925 929.
2. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 1990 265 : 5292 5295.
3. Collart FR, Huberman E. Cloning and sequence analysis of the human and Chinese hamster inosine-5′-monophosphate dehydrogenase cDNAs. J Biol Chem 1988 263 : 15769 15772.
4. Gu JJ, Stegmann S, Gathy K, Murray R, Laliberte J, Ayscue L, Mitchell BS. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J Clin Invest 2000 106 : 599 606.
5. Gu JJ, Spychala J, Mitchell BS. Regulation of the human inosine monophosphate dehydrogenase type I gene. Utilization of alternative promoters. J Biol Chem 1997 272 : 4458 4466.
6. Zimmerman AG, Sphycala J, Mitchell BS. Characterization of the human inosine-5′-monophosphate dehydrogenase type II gene. J Biol Chem 1995 270 : 6808 6814.
7. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001 24 : 645 663.
8. Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 2007 39 : 88 93.
9. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003 14 : 2381 2386.
10. Pelletier RP, Akin B, Henry ML, Bumgardner GL, Elkhammas EA, Rajab A, Ferguson RM. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003 17 : 200 205.
11. van Gelder T, Shaw LM. The rationale for and limitation of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005 244 253.
12. Burkhart C, Heusser C, Morris RE, Raulf F, Weckbecker G, Weitz-Schmidt G, Welzenbach K. Pharmacodynamics in the development of new immunosuppressive drugs. Ther Drug Monit 2004 26 : 588 592.
13. Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L, Mai I, Roots I, Neumayer HH. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000 38 : 1213 1216.
14. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I, Einecke G, Waiser J, Neumayer HH, Budde K. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004 4 : 2045 2051.
15. Kamar N, Glander P, Nolting J, Böhler T, Hambach P, Liefeldt L, Neumayer HH, Klupp J, Budde K. Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantation. Transplant Proc 2006 38 : 2292 2294.
16. Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999 65 : 640 648.
17. Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Scand J Clin Lab Invest 2006 66 : 31 44.
18. Weigel G, Griesmacher A, Zuckermann AO, Laufer G, Mueller MM. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 2001 69 : 137 144.
19. Bremer S, Mandla R, Vethe NT, Rasmussen I, Rootwelt H, Line PD, Midtvedt K, Bergan S. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation 2008 85 : 55 61.
20. Goldsmith D, Carrey EA, Edbury S, Smolenski RT, Jagodzinski P, Simmonds HA. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci 2004 107 : 63 8.
21. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Marcussen N, Mihatsch MJ, Nadasdy T, Nickerson P, Olsen TS, Papadimitriou JC, Randhawa PS, Rayner DC, Roberts I, Rose S, Rush D, Salinas-Madrigal L, Salomon DR, Sund S, Taskinen E, Trpkov K, Yamaguchi Y. The Banff97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713 723. (Pubitemid 29082898)
22. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ. The Banff '05 Meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 2007 7 : 518 526.
23. Pawinski T, Hale M, Korecka M, Fitzimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002 48 : 1497 1504.
24. van Hest RM, Mathôt RA, Vulto AG, Le Meur Y, van Gelder T. Mycophenolic acid in diabetic renal transplant recipients. Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2004 26 : 620 625.
25. de Loor H, Naesens M, Verbeke K, Vanrenterghem Y, Kuypers DR. Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. Clin Chim Acta 2008 389 : 87 92.
26. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995 41 : 1011 1017.
27. Shipkova M, Niedmann PD, Armstrong VW, Schütz E, Wieland E, Shaw LM, Oellerich M. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998 44 : 1481 1488.
28. Patel CG, Mendonza AE, Akhlaghi F, Majid O, Trull AK, Lee T, Holt DW. Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004 813 : 287 294.
29. Böyum A. Isolation of leucocytes from human blood. A two-phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent. Scand J Clin Lab Invest 1968 97 : 9 29.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193 : 265 275.
31. Glander P, Braun KP, Hambach P, Bauer S, Mai I, Roots I, Waiser J, Fritsche L, Neumayer HH, Budde K. Non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001 34 : 543 549.
32. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006 28 : 145 154. (Pubitemid 44314941)
33. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007 7 : 2496 2503.
34. Albrecht W, Storck M, Pfetsch E, Martin W, Abendroth D. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5′-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit 2000 22 : 283 294.
35. Glander P, Sombogaard F, Budde K, Gelder TV, Hambach P, Liefeldt L, Lorkowski C, Mai M, Neumayer HH, Vulto AG, Mathot RA. Improved assay for the nonradioactive determination of inosine 5′-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit 2009 31 : 351 359.
36. Budde K, Bauer S, Hambach P, Hahn U, Röblitz H, Mai I, Diekmann F, Neumayer HH, Glander P. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007 7 : 888 898. (Pubitemid 46481185)
37. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001 23 : 119 128.
38. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by Mrp2 in rats. J Pharmacol Exp Ther 2004 309 : 1029 1035.
39. Shaw LM, Korecka M, Venkataramanan R, Golberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamic and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003 3 : 534 542.
40. Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol 2007 2 : 1062 1072.
41. Sanquer S, Maison P, Tomkiewicz C, Macquin-Mavier I, Legendre C, Barouki R, Lang P. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther 2008 83 : 328 335.